Interstitial Cystitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest EMA, PDMA, FDA Approvals by DelveInsight | Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics

The Interstitial Cystitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
DelveInsight's "Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast-2032 [https://www.delveinsight.com/report-store/interstitial-cystitis-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] report offers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Interstitial Cystitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Interstitial Cystitis Market Forecast [https://www.delveinsight.com/report-store/interstitial-cystitis-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Some of the key facts of the Interstitial Cystitis Market Report:

*
The Interstitial Cystitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

*
According to DelveInsight's analysis, the interstitial cystitis market size reached USD 1.8 billion in 2021 across the 7MM, and is expected to grow with a significant CAGR by 2032.

*
DelveInsight's analysis reveals that the overall diagnosed prevalent population of interstitial cystitis in the 7MM was reported as 2.5 million in 2021. Within this, the diagnosed prevalent population of interstitial cystitis patients in the United States specifically was identified to be 1.6 million in the same year.

*
Key Interstitial Cystitis Companies: Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Addex Therapeutics, Seikagaku Corporation, UCB, Alivio Therapeutics, Imbrium Therapeutics, Ironwood Pharmaceuticals, and others

*
Key Interstitial Cystitis Therapies: Elmiron, RIMSO-50, KRP-116D, Certolizumab pegol (Cimzia), LP-08, GRT6010, ASP6294, SI-722, and others

*
The total diagnosed prevalent population of Interstitial Cystitis in the 7 major markets was found to be 2,343,164 in 2018. In case of Interstitial Cystitis patients in the United States, the diagnosed prevalent cases were found to be 1,512,400 cases.

*
The prevalent population of Interstitial Cystitis in the United States was found to be 5,894,905 in 2018.

*
DelveInsight has analyzed severity-based data for Interstitial Cystitis. Interstitial Cystitis can be divided as three types based on this data, namely, mild, moderate and severe type. It was found that in the United States the number of cases of mild, moderate and severe were 544,500, 756,200 and 211,800 respectively.

*
Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in the diagnosed prevalent population of Interstitial Cystitis. Owing to the positive outcomes of the several products during the developmental stage by key players such as Kyorin Pharmaceutical, UCB Pharma, Lipella Pharmaceuticals, Grunenthal and Astellas Pharma, the market is expected to witness a significant positive shift in the Interstitial Cystitis Market Size.

*
The Interstitial Cystitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Interstitial Cystitis pipeline products will significantly revolutionize the Interstitial Cystitis market dynamics.

*
In Oct 2023, Glycologix, Inc. announced the treatment of the first patient in a pilot clinical study evaluating GLX-100 as a novel treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The multi-center pilot trial is designed to assess the safety, tolerability and effectiveness of GLX-100 in participants with IC/BPS and is expected to enroll up to 40 women with results anticipated in 2024.

*
In June 2023, Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the first patient has been enrolled in a 4-arm Phase 2 trial2 of AlenuraTM, comparing the product candidate to both of its individual components (heparin and lidocaine)3 as well as placebo.

Interstitial Cystitis Overview

Interstitial Cystitis, also known as Painful Bladder Syndrome, is a persistent condition characterized by bladder pressure, bladder pain, and occasionally pelvic discomfort. The severity of pain can vary from mild to severe levels. The bladder, a hollow muscular organ responsible for storing urine, expands until it's full, signaling the brain through pelvic nerves when it's time to urinate, typically prompting the urge to urinate. However, with IC, these signals become confused, leading patients to feel the need to urinate more frequently and with smaller volumes of urine than usual. This condition predominantly affects women and can significantly impact their quality of life over the long term. While there's no definitive cure, medications and various therapies may provide some relief.

There are two main types of IC: Non-Ulcerative, which accounts for approximately 90% of IC cases, is characterized by pinpoint hemorrhages known as glomerulations. The other type, Ulcerative, affects about 5-10% of patients and is primarily identified by Hunner's ulcers, along with patches that bleed on the bladder walls. Hunner's ulcers, also referred to as "Hunner's lesions" or "Hunner's patches," are specific areas of inflammation on the bladder wall that define the "classic" form of IC. While Hunner's ulcers are a key diagnostic feature for IC, this classic form only affects a small percentage of patients, typically presenting with more severe symptoms compared to those with non-ulcerative IC.

Get a Free sample for the Interstitial Cystitis Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast [https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Interstitial Cystitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Interstitial Cystitis Epidemiology Segmentation:

The Interstitial Cystitis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Interstitial Cystitis

*
Prevalent Cases of Interstitial Cystitis by severity

*
Gender-specific Prevalence of Interstitial Cystitis

*
Diagnosed Cases of Episodic and Chronic Interstitial Cystitis

Download the report to understand which factors are driving Interstitial Cystitis epidemiology trends @ Interstitial Cystitis Epidemiology Forecast [https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Interstitial Cystitis Therapies

*
Elmiron

*
RIMSO-50

*
KRP-116D

*
Certolizumab pegol (Cimzia)

*
LP-08

*
GRT6010

*
ASP6294

*
SI-722

Interstitial Cystitis Key Companies

*
Merck & Co

*
Teva Pharmaceutical Industries

*
Integrative Therapeutics

*
Lipella Pharmaceuticals

*
Addex Therapeutics

*
Seikagaku Corporation

*
UCB

*
Alivio Therapeutics

*
Imbrium Therapeutics

*
Ironwood Pharmaceuticals

Discover more about therapies set to grab major Interstitial Cystitis market share @ Interstitial Cystitis Treatment Landscape [https://www.delveinsight.com/report-store/interstitial-cystitis-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Interstitial Cystitis Market Outlook

As per the Interstitial Cystitis Association (ICA), interstitial cystitis (IC) is a bladder disorder typically characterized by a variety of symptoms. Most individuals with IC experience recurring pelvic pain, pressure, or discomfort in the bladder and pelvic area, along with urinary frequency and urgency (a strong urge to urinate). IC is also known by various other names such as painful bladder syndrome (PBS), bladder pain syndrome (BPS), and chronic pelvic pain. It is estimated that approximately 3-8 million women in the United States, constituting about 3-6% of all women in the US, may suffer from IC. Additionally, 1-4 million men are affected by IC, although this number is likely underestimated because IC in men may often be misdiagnosed as another condition, such as chronic prostatitis/chronic pelvic pain syndrome.

Oral pentosan polysulfate sodium (PPS) and intravesical dimethyl sulfoxide (DMSO) are the only treatments approved by the US Food and Drug Administration (FDA) for alleviating IC symptoms. Fortunately, various other therapies are commonly utilized either individually or in combination for managing IC. Among orally administered therapies, only Elmiron (Pentosan polysulfate sodium; Janssen Pharmaceuticals) is FDA-approved for IC treatment, receiving approval in September 1996. Pentosan Polysulfate is a semi-synthetic heparin-like glycosaminoglycan. On the other hand, intravesical instillations involving anesthetic solutions are employed to alleviate bladder pain, along with heparin agents believed to repair damaged urothelium. The American Urological Association's practice guideline for IC suggests bladder instillations as a second-line treatment option when dietary modifications, stress management, and over-the-counter products prove insufficient. Bladder instillations, also known as bladder cocktails, involve introducing mixtures of medications directly into the bladder.

Common types of instillations include Alkalinized Lidocaine and Heparin, DMSO, Sodium Hyaluronate, and BCG. Among these, Dimethyl sulfoxide (DMSO, marketed as RIMSO-50 by Mylan Pharmaceutical) was the first and remains the only FDA-approved bladder instillation specifically for Interstitial Cystitis (IC), receiving approval in 1978. Its precise mechanism of action is not fully understood, but it is believed to have several beneficial effects including anti-inflammatory, antispasmodic, pain-relieving properties, and increasing bladder capacity by breaking down scar tissue and preventing the formation of collagen, a protein involved in scar tissue formation.

Current IC treatment strategies involve the use of interventions either as single therapies (monotherapies) or in combination (combination therapies). Monotherapy options include oral medications, intravesical instillations, and other treatment modalities, while combination therapy entails using one or more of these therapies together.

Scope of the Interstitial Cystitis Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Interstitial Cystitis Companies: Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Addex Therapeutics, Seikagaku Corporation, UCB, Alivio Therapeutics, Imbrium Therapeutics, Ironwood Pharmaceuticals, and others

*
Key Interstitial Cystitis Therapies: Elmiron, RIMSO-50, KRP-116D, Certolizumab pegol (Cimzia), LP-08, GRT6010, ASP6294, SI-722, and others

*
Interstitial Cystitis Therapeutic Assessment: Interstitial Cystitis current marketed and Interstitial Cystitis emerging therapies

*
Interstitial Cystitis Market Dynamics: Interstitial Cystitis market drivers and Interstitial Cystitis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Interstitial Cystitis Unmet Needs, KOL's views, Analyst's views, Interstitial Cystitis Market Access and Reimbursement

Table of Contents

1. Interstitial Cystitis Market Report Introduction

2. Executive Summary for Interstitial Cystitis

3. SWOT analysis of Interstitial Cystitis

4. Interstitial Cystitis Patient Share (%) Overview at a Glance

5. Interstitial Cystitis Market Overview at a Glance

6. Interstitial Cystitis Disease Background and Overview

7. Interstitial Cystitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Interstitial Cystitis

9. Interstitial Cystitis Current Treatment and Medical Practices

10. Interstitial Cystitis Unmet Needs

11. Interstitial Cystitis Emerging Therapies

12. Interstitial Cystitis Market Outlook

13. Country-Wise Interstitial Cystitis Market Analysis (2019-2032)

14. Interstitial Cystitis Market Access and Reimbursement of Therapies

15. Interstitial Cystitis Market Drivers

16. Interstitial Cystitis Market Barriers

17. Interstitial Cystitis Appendix

18. Interstitial Cystitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Interstitial Cystitis Pipeline

"Interstitial Cystitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Interstitial Cystitis market. A detailed picture of the Interstitial Cystitis pipeline landscape is provided, which includes the disease overview and Interstitial Cystitis treatment guidelines.

Interstitial Cystitis Epidemiology

DelveInsight's 'Interstitial Cystitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Interstitial Cystitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=interstitial-cystitis-market-report-2032-epidemiology-data-pipeline-therapies-latest-ema-pdma-fda-approvals-by-delveinsight-merck-co-teva-pharmaceutical-industries-integrative-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.